Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers

23 Oct 2020

Abstract excerpt

mutation has been shown to be associated with poor clinicopathologic characteristics and survival in patients with BTCs, indicating that p53 plays an important role in the treatment of these cancers. Herein, we comprehensively reviewed previous BTC preclinical research and early clinical trials in terms of p53, as well as novel p53-targeted treatment, alone or in combination with either chemotherapy or other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Hedgehog Signaling Pathway Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33113997
DOI: 10.3390/biom10111474

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract CancersPMID 33113997Read ↗

Advances in understanding the roles of TP53 mutations in pancreatic and hepatobiliary cancers.Semantic proximity Read ↗

Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy.Semantic proximity Read ↗

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Semantic proximity Read ↗

Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer.Semantic proximity Read ↗

Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.Semantic proximity Read ↗

Emerging molecular target antagonists for the treatment of biliary tract cancer.Semantic proximity Read ↗

Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives.Semantic proximity Read ↗

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.Semantic proximity Read ↗

Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.Semantic proximity Read ↗

Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case SeriesSemantic proximity Read ↗

Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.Semantic proximity Read ↗

p53 as a biomarker and potential target in gastrointestinal stromal tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.